Please login to the form below

Not currently logged in
Email:
Password:

CellCept

This page shows the latest CellCept news and features for those working in and with pharma, biotech and healthcare.

Lupus trial hailed as a success despite patient deaths

Lupus trial hailed as a success despite patient deaths

Voclosporin or placebo were given to patients on top of therapy with Roche's transplant rejection drug CellCept (mycophenolate mofetil) in the study, the current standard of care for lupus nephritis,

Latest news

  • CHMP October meeting gives recommendations for Pfizer and MSD CHMP October meeting gives recommendations for Pfizer and MSD

    The Committee also advocated additional measures to prevent the use of Roche's Cellcept (mycophenolate) during pregnancy.

  • Lupus – a 'great imitator'

    Immunosuppressants such as mycophenolate mofetil (CellCept, Roche) and tacrolimus (Prograf, Astellas Pharma) are used to inhibit the body's production of auto-antibodies, which are responsible for the classical symptoms of

  • FDA take hard line on GSK lupus drug

    The chemotherapy drug cyclophosphamide and Roche's immunosuppressant drug CellCept (mycophenolate mofetil) are often used off-label for lupus but have not been approved for the indication by the FDA.

  • R&D news in brief

    Cellcept shows promise. Immune-suppression drug CellCept works better than the standard chemotherapy medication in treating kidney complications from lupus, according to a new study. ... CellCept is made by Hoffmann-La Roche ad is approved by the US Food

  • An unexpected turn

    Amitiza (Takeda Pharmaceuticals). Irritable Bowel Syndrome. US. Mycophenolate mofetil (Cellcept; Roche) is an immunosupressant commonly used for treating and preventing transplant rejection.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics